zalmoxis
molmed spa - alogenskih t celice, gensko spremenjene z retrovirusni vektor kodiranje za skrajšani obliki ljudi nizko afiniteto živca rastni faktor receptor (Δlngfr) in herpes simplex virus timidin-kinazo (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoxis je indiciran kot dodatno zdravljenje pri haploidentični hematopoetski presaditvi matičnih celic (hsct) pri odraslih bolnikih z visokim tveganjem hematoloških malignomov.
arti-cell forte
boehringer ingelheim vetmedica gmbh - chondrogenic povzroča konjskega allogeneic periferne krvi, pridobljenih mesenchymal stem cells - druga zdravila za motnje mišično-skeletnega sistema - konji - zmanjšanje blage do zmerne periodično lameness, povezane z ne-septic vnetje sklepov pri konjih.
advagraf
astellas pharma europe bv - takrolimus - zavrnitev presadka - imunosupresivi - preprečevanje zavrnitve presadka pri prejemnikih alogenskega presadka ledvic ali jeter. zdravljenje zavrnitve alogenskega presadka, odpornega na zdravljenje z drugimi imunosupresivnimi zdravili pri odraslih bolnikih.
prevymis
merck sharp & dohme b.v. - letermovir - okužbe s citomegalovirusom - antivirusi za sistemsko uporabo - prevymis je indicirano za profilakso reaktivacije citomegalovirusom (cmv) in bolezni pri odraslih serološko cmv prejemniki [r +] alogenskih krvotvornih matičnih celic presaditev (hsct). upoštevati je treba uradne smernice za ustrezno uporabo protivirusnih agenti.
envarsus
chiesi farmaceutici s.p.a. - takrolimus - zavrnitev presadka - imunosupresivi - preprečevanje zavrnitve presadka pri prejemnikih alogenskega presadka ledvic ali jeter. zdravljenje zavrnitve alogenskega presadka, odpornega na zdravljenje z drugimi imunosupresivnimi zdravili pri odraslih bolnikih.
modigraf
astellas pharma europe b.v. - takrolimus - zavrnitev presadka - imunosupresivi - preprečevanje zavrnitve presadka pri prejemnikih alogenskega presadka pri odraslih in pediatričnih, ledvičnih, jetrnih ali srčnih. zdravljenje allograft zavrnitev odporne na zdravljenje z drugimi imunosupresivnimi zdravili pri odraslih in pediatričnih bolnikih.
tacforius
teva b.v. - takrolimus monohidrat - liver transplantation; kidney transplantation - imunosupresivi - preprečevanje zavrnitve presadka pri prejemnikih alogenskega presadka ledvic ali jeter. zdravljenje zavrnitve alogenskega presadka, odpornega na zdravljenje z drugimi imunosupresivnimi zdravili pri odraslih bolnikih.
mycamine
astellas pharma europe b.v. - mikafungin - kandidoza - antimikotiki za sistemsko uporabo - mycamine je indiciran za:odrasli, mladostniki ≥ 16 let in elderlytreatment za invazivne kandidoze;zdravljenje ezofagealni kandidoze pri bolnikih, za katere intravensko zdravljenje je primerno;preventivo candida okužbe pri bolnikih, ki opravljajo allogeneic haematopoietic stem-cell presaditve ali bolniki, ki se pričakuje, da so neutropenia (absolutno neutrophil štetje < 500 celic/µl) za 10 ali več dni. otroci (vključno z novorojenčkih) in mladostnikih < 16 let agetreatment za invazivne kandidoze. profilaksa candida okužbe pri bolnikih, ki opravljajo allogeneic haematopoietic stem-cell presaditve ali bolniki, ki se pričakuje, da so neutropenia (absolutno neutrophil štetje < 500 celic/µl) za 10 ali več dni. odločitev za uporabo mycamine je treba upoštevati morebitno tveganje za razvoj jetrnih tumorjev. mycamine bi zato lahko uporabljajo le, če druge antifungals niso primerne.
jayempi
nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.